Disitamab price, dosage specifications and drug purchase reference

Vedisitomab (Disitamab) is a targeted antibody drug used to treat specific solid tumors, mainly for patients with HER2 positive tumors. It achieves anti-tumor effects by specifically binding to the HER2 receptor on the surface of tumor cells, and has shown good efficacy and tolerability in clinical studies. The emergence of this drug provides a new treatment option for some patients with advanced tumors.

In terms of dosage and specifications, vedicitomab is usually administered via intravenous injection, and the specific dosage needs to be adjusted based on the patient's body surface area and doctor's assessment. The common clinical dosage regimen is a fixed mg/m dosage calculated based on body surface area, administered once per cycle. The specific course and frequency of treatment are determined by the attending physician based on the patient's condition and tolerance. Reasonable dosage can maximize efficacy while reducing the risk of adverse reactions.

In terms of price, vidicitomab has been launched in the country and has been included in medical insurance reimbursement items. It is understood that its domestic market price is less than 3,000yuan per tube. If patients need to use it, they can reduce their financial burden through medical insurance reimbursement. This allows more eligible patients to obtain drugs at a more affordable cost and achieve standardized treatment.

In terms of drug purchase channels, patients can purchase Vidicitomab directly from hospital pharmacies that are qualified for oncology medication. Since the drug is a prescription drug, it needs to be evaluated and prescribed by a doctor before use. During the purchase and use process, patients should follow the doctor's guidance, complete the medication according to the course of treatment, and conduct regular reviews to evaluate the efficacy and adjust the treatment plan to ensure the safety and effectiveness of the medication.

Keyword tags: vedicitumab, HER2positive tumors, ADCDrug, price, dosage specification

Reference materials:https://pubmed.ncbi.nlm.nih.gov/38940019/